Skip to content

Counterfeit Ozempic Indictment Lands as Retatrutide Data Hits EASD — September 30, 2026

September 30, 2026 · 9 min

Show notes

Counterfeit Ozempic allegedly sourced from China is at the center of a federal indictment of two Indian nationals in Tampa. At EASD in Milan, Lilly-funded Phase 3 retatrutide results appear in The Lancet, and a Novo-funded registry study finds no semaglutide–pancreatic cancer link.

In this episode
  1. Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page — The Front Page

    Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page # Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme Swapnadip Roy and Vicky Ramancha were indicted on smuggling and conspiracy charges for distributing counterfeit Ozempic, with Roy appearing in a Florida federal court following his extradition from Italy. via CBS…

  2. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes — Finviz

    Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes # Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes By PR Newswire | September 29, 2026, 6:00 PM In…

  3. Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan — Fierce Pharma

    Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan # Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milan By Fraiser Kansteiner Sep 29, 2026 11:20am Finding unique features to pin one’s GLP-1 pitch on has become increasingly important both for developers hoping to catch the next wave of obesity treatments and for Novo’s and Lilly’s…

  4. Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert! — EurekAlert!

    Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert! News Release 28-Sep-2026 # Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway New research to be presented at the Annual Meeting of…

  5. Step Back — With an alleged counterfeit Ozempic smuggling scheme now under investigation, how can patients tell whether a GLP-1 prescription came through a legitimate, FDA-regulated supply chain—and what should they do if the packaging, pharmacy, or product seems suspicious?Background sources

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].

All episodes of GLP-1 Daily: Ozempic & Wegovy News

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.